Cetuximab Plus Platinum and Taxane-based Chemotherapy, Followed by Avelumab and Cetuximab, as First-line Treatment for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Patients With a PD-L1 Combined Positive Score (CPS)≥1≤19.

head and neck squamous cell carcinoma (hnscc), recurrent head and neck cancer, metastatic head and neck cancer, head and neck neoplasms, squamous cell carcinoma, cetuximab, avelumab, anti-egfr therapy, platinum-based chemotherapy, taxane-based chemotherapy, pd-l1 combined positive score (cps), interventional